Bone marrow transplantation for diamond-blackfan anemia

Vivek Roy, Waleska S. Pérez, Mary Eapen, Judith C W Marsh, Marcelo Pasquini, Ricardo Pasquini, Mahmoud M. Mustafa, Christopher N. Bredeson, S. E. Ball, B. M. Camitta, R. P. Gale, T. G. Gross, G. A. Hale, J. T. Horan, J. M. Lipton, C. M. Niemeyer, P. J. Orchard

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Patients with Diamond-Blackfan anemia (DBA) who are unresponsive to or intolerant of corticosteroids, experience treatment failure with other treatments, develop additional cytopenias or clonal disease, or opt for curative therapy are often treated with allogeneic bone marrow transplantation. We studied the transplantation outcomes of 61 DBA patients whose data were reported to the International Bone Marrow Transplant Registry between 1984 and 2000. The median age was 7 years (range, 1-32 years). Among 55 patients with available transfusion information, 35 (64%) had received ≥20 units of blood before transplantation. Most patients (67%) received their bone marrow grafts from an HLA-matched related donor. The median time to neutrophil recovery was 17 days (range, 10-119 days) and to platelet recovery was 23 days (range, 9-119 days). Five patients did not achieve neutrophil engraftment. The 100-day mortality was 18% (95% confidence interval, 10%-29%). Grade II to IV acute graft-versus-host disease occurred in 28% (range, 17%-39%) and chronic graft-versus-host disease in 26% (range, 15%-39%). The 3-year probability of overall survival was 64% (range, 50%-74%). In univariate analysis, a Karnofsky score ≥90 and transplantation from an HLA-identical sibling donor were associated with better survival. These data suggest that allogeneic bone marrow transplantation is effective for the treatment of DBA. Transplantation before deterioration of the performance status and from an HLA-identical sibling donor may improve survival.

Original languageEnglish (US)
Pages (from-to)600-608
Number of pages9
JournalBiology of Blood and Marrow Transplantation
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2005

Fingerprint

Diamond-Blackfan Anemia
Bone Marrow Transplantation
Transplantation
Homologous Transplantation
Tissue Donors
Graft vs Host Disease
Survival
Siblings
Neutrophils
Bone Marrow
Transplants
Treatment Failure
Registries
Adrenal Cortex Hormones
Therapeutics
Blood Platelets
Confidence Intervals
Mortality

Keywords

  • Bone marrow transplantation
  • Congenital anemia
  • Diamond-Blackfan anemia

ASJC Scopus subject areas

  • Transplantation

Cite this

Roy, V., Pérez, W. S., Eapen, M., Marsh, J. C. W., Pasquini, M., Pasquini, R., ... Orchard, P. J. (2005). Bone marrow transplantation for diamond-blackfan anemia. Biology of Blood and Marrow Transplantation, 11(8), 600-608. https://doi.org/10.1016/j.bbmt.2005.05.005

Bone marrow transplantation for diamond-blackfan anemia. / Roy, Vivek; Pérez, Waleska S.; Eapen, Mary; Marsh, Judith C W; Pasquini, Marcelo; Pasquini, Ricardo; Mustafa, Mahmoud M.; Bredeson, Christopher N.; Ball, S. E.; Camitta, B. M.; Gale, R. P.; Gross, T. G.; Hale, G. A.; Horan, J. T.; Lipton, J. M.; Niemeyer, C. M.; Orchard, P. J.

In: Biology of Blood and Marrow Transplantation, Vol. 11, No. 8, 01.08.2005, p. 600-608.

Research output: Contribution to journalArticle

Roy, V, Pérez, WS, Eapen, M, Marsh, JCW, Pasquini, M, Pasquini, R, Mustafa, MM, Bredeson, CN, Ball, SE, Camitta, BM, Gale, RP, Gross, TG, Hale, GA, Horan, JT, Lipton, JM, Niemeyer, CM & Orchard, PJ 2005, 'Bone marrow transplantation for diamond-blackfan anemia', Biology of Blood and Marrow Transplantation, vol. 11, no. 8, pp. 600-608. https://doi.org/10.1016/j.bbmt.2005.05.005
Roy, Vivek ; Pérez, Waleska S. ; Eapen, Mary ; Marsh, Judith C W ; Pasquini, Marcelo ; Pasquini, Ricardo ; Mustafa, Mahmoud M. ; Bredeson, Christopher N. ; Ball, S. E. ; Camitta, B. M. ; Gale, R. P. ; Gross, T. G. ; Hale, G. A. ; Horan, J. T. ; Lipton, J. M. ; Niemeyer, C. M. ; Orchard, P. J. / Bone marrow transplantation for diamond-blackfan anemia. In: Biology of Blood and Marrow Transplantation. 2005 ; Vol. 11, No. 8. pp. 600-608.
@article{197a8676601e43d1b48f6f485ee97ca2,
title = "Bone marrow transplantation for diamond-blackfan anemia",
abstract = "Patients with Diamond-Blackfan anemia (DBA) who are unresponsive to or intolerant of corticosteroids, experience treatment failure with other treatments, develop additional cytopenias or clonal disease, or opt for curative therapy are often treated with allogeneic bone marrow transplantation. We studied the transplantation outcomes of 61 DBA patients whose data were reported to the International Bone Marrow Transplant Registry between 1984 and 2000. The median age was 7 years (range, 1-32 years). Among 55 patients with available transfusion information, 35 (64{\%}) had received ≥20 units of blood before transplantation. Most patients (67{\%}) received their bone marrow grafts from an HLA-matched related donor. The median time to neutrophil recovery was 17 days (range, 10-119 days) and to platelet recovery was 23 days (range, 9-119 days). Five patients did not achieve neutrophil engraftment. The 100-day mortality was 18{\%} (95{\%} confidence interval, 10{\%}-29{\%}). Grade II to IV acute graft-versus-host disease occurred in 28{\%} (range, 17{\%}-39{\%}) and chronic graft-versus-host disease in 26{\%} (range, 15{\%}-39{\%}). The 3-year probability of overall survival was 64{\%} (range, 50{\%}-74{\%}). In univariate analysis, a Karnofsky score ≥90 and transplantation from an HLA-identical sibling donor were associated with better survival. These data suggest that allogeneic bone marrow transplantation is effective for the treatment of DBA. Transplantation before deterioration of the performance status and from an HLA-identical sibling donor may improve survival.",
keywords = "Bone marrow transplantation, Congenital anemia, Diamond-Blackfan anemia",
author = "Vivek Roy and P{\'e}rez, {Waleska S.} and Mary Eapen and Marsh, {Judith C W} and Marcelo Pasquini and Ricardo Pasquini and Mustafa, {Mahmoud M.} and Bredeson, {Christopher N.} and Ball, {S. E.} and Camitta, {B. M.} and Gale, {R. P.} and Gross, {T. G.} and Hale, {G. A.} and Horan, {J. T.} and Lipton, {J. M.} and Niemeyer, {C. M.} and Orchard, {P. J.}",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2005.05.005",
language = "English (US)",
volume = "11",
pages = "600--608",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Bone marrow transplantation for diamond-blackfan anemia

AU - Roy, Vivek

AU - Pérez, Waleska S.

AU - Eapen, Mary

AU - Marsh, Judith C W

AU - Pasquini, Marcelo

AU - Pasquini, Ricardo

AU - Mustafa, Mahmoud M.

AU - Bredeson, Christopher N.

AU - Ball, S. E.

AU - Camitta, B. M.

AU - Gale, R. P.

AU - Gross, T. G.

AU - Hale, G. A.

AU - Horan, J. T.

AU - Lipton, J. M.

AU - Niemeyer, C. M.

AU - Orchard, P. J.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Patients with Diamond-Blackfan anemia (DBA) who are unresponsive to or intolerant of corticosteroids, experience treatment failure with other treatments, develop additional cytopenias or clonal disease, or opt for curative therapy are often treated with allogeneic bone marrow transplantation. We studied the transplantation outcomes of 61 DBA patients whose data were reported to the International Bone Marrow Transplant Registry between 1984 and 2000. The median age was 7 years (range, 1-32 years). Among 55 patients with available transfusion information, 35 (64%) had received ≥20 units of blood before transplantation. Most patients (67%) received their bone marrow grafts from an HLA-matched related donor. The median time to neutrophil recovery was 17 days (range, 10-119 days) and to platelet recovery was 23 days (range, 9-119 days). Five patients did not achieve neutrophil engraftment. The 100-day mortality was 18% (95% confidence interval, 10%-29%). Grade II to IV acute graft-versus-host disease occurred in 28% (range, 17%-39%) and chronic graft-versus-host disease in 26% (range, 15%-39%). The 3-year probability of overall survival was 64% (range, 50%-74%). In univariate analysis, a Karnofsky score ≥90 and transplantation from an HLA-identical sibling donor were associated with better survival. These data suggest that allogeneic bone marrow transplantation is effective for the treatment of DBA. Transplantation before deterioration of the performance status and from an HLA-identical sibling donor may improve survival.

AB - Patients with Diamond-Blackfan anemia (DBA) who are unresponsive to or intolerant of corticosteroids, experience treatment failure with other treatments, develop additional cytopenias or clonal disease, or opt for curative therapy are often treated with allogeneic bone marrow transplantation. We studied the transplantation outcomes of 61 DBA patients whose data were reported to the International Bone Marrow Transplant Registry between 1984 and 2000. The median age was 7 years (range, 1-32 years). Among 55 patients with available transfusion information, 35 (64%) had received ≥20 units of blood before transplantation. Most patients (67%) received their bone marrow grafts from an HLA-matched related donor. The median time to neutrophil recovery was 17 days (range, 10-119 days) and to platelet recovery was 23 days (range, 9-119 days). Five patients did not achieve neutrophil engraftment. The 100-day mortality was 18% (95% confidence interval, 10%-29%). Grade II to IV acute graft-versus-host disease occurred in 28% (range, 17%-39%) and chronic graft-versus-host disease in 26% (range, 15%-39%). The 3-year probability of overall survival was 64% (range, 50%-74%). In univariate analysis, a Karnofsky score ≥90 and transplantation from an HLA-identical sibling donor were associated with better survival. These data suggest that allogeneic bone marrow transplantation is effective for the treatment of DBA. Transplantation before deterioration of the performance status and from an HLA-identical sibling donor may improve survival.

KW - Bone marrow transplantation

KW - Congenital anemia

KW - Diamond-Blackfan anemia

UR - http://www.scopus.com/inward/record.url?scp=22344441866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344441866&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2005.05.005

DO - 10.1016/j.bbmt.2005.05.005

M3 - Article

C2 - 16041310

AN - SCOPUS:22344441866

VL - 11

SP - 600

EP - 608

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -